 Home > Active Ingredient News > Antitumor Therapy > J Clin Oncol: Letrozole plus Abbesilil for recurrent ER-positive endometrial cancer

J Clin Oncol: Letrozole plus Abbesilil for recurrent ER-positive endometrial cancer

 Last Update: 2022-10-12
 Source: Internet
 Author: User

Tags

1 4 socket

vanilloid receptor

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Estrogen receptor (ER)-positive endometrial carcinoma (EC) is characterized by PI3K pathway mutations in about 90% of cases and about 80% of cases carrying receptor tyrosine kinase (RTK)/RAS/β-catenin (CTNNB1) pathway variants

The researchers speculate that the combined application of the aromatase inhibitor letrozole and the CDK4/6 inhibitor abemaciclib may benefit significantly in

The study is a phase II, two-stage clinical trial designed to evaluate the efficacy and safety

As of December 3, 2021, a total of 30 patients have received the study treatment; Fifteen (50%) patients had previously received hormone therapy

The most common treatment-related adverse effects of grade 3 and above are neutropenia (20%) and anemia (17%)

Exploratory tumor analysis revealed several candidate predictors associated with treatment response mechanisms (CTNNB1, KRAS and CDKN2A mutations, TP53 mutations [associated with no response to treatment]) that require independent validation

Overall, the findings show that letrozole plus Abbesilil exhibits encouraging sustained therapeutic activity

Original Source:

Panagiotis A.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Bulk Peptides Kisspeptin 10 (human) /Kisspeptin 10/ Kisspeptin-10 Acetate CAS 374675-21-5

CAS No.: 374675-21-5

Pharmacy Grade

$10-13/UNIT FOB

Cediranib

CAS No.: 288383-20-0

$22/KG EXW

Upadacitinib hemihydrate API

CAS No.: 2050057-56-0

Pharmacy Grade

$35-45/G FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

80 20 company(94)

united states logo(227)

ups united states(221)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.